Brief: Angion Announces Discontinuation Of Phase 2 Trial Of ANG-3070 In Patients With Primary Proteinuric Kidney Disease

Elicio Therapeutics

29/06/2022 22:48

June 29 (Reuters) - Angion Biomedica Corp  ANGN.O :
    * ANGION ANNOUNCES DISCONTINUATION OF PHASE 2 TRIAL OF
ANG-3070 IN
PATIENTS WITH PRIMARY PROTEINURIC KIDNEY DISEASE
    * ANGION BIOMEDICA CORP - TRIAL, WHICH BEGAN ENROLLING
PATIENTS IN
DECEMBER 2021, IS BEING DISCONTINUED IN INTEREST OF PATIENT
SAFETY
    * ANGION - TRIAL BEING DISCONTINUED BASED ON REASSESSMENT OF
RISK/BENEFIT PROFILE OF ANG-3070 IN PATIENTS WITH ESTABLISHED
SERIOUS KIDNEY DISEASE
    * ANGION - REASSESSMENT CONDUCTED AFTER OCCURRENCE OF
POTENTIAL
SAFETY SIGNAL OF UNEXPECTED, SUBSTANTIAL DECLINE IN KIDNEY
FUNCTION IN PATIENT IN TREATMENT ARM
    * ANGION BIOMEDICA CORP - REASSESSMENT TOOK INTO ACCOUNT
NUMBER OF
FACTORS, INCLUDING EVALUATION OF TOTALITY OF DATA REVIEWED WITH
RESPECT TO ANG-3070
    * ANGION BIOMEDICA CORP - BELIEVE DISCONTINUATION OF JUNIPER
STUDY
IS IN BEST INTEREST OF PATIENTS
    * ANGION BIOMEDICA CORP - EXPECTS TO REPORT CASH AND CASH
EQUIVALENTS OF GREATER THAN $60 MILLION AT END OF Q2

Source text for Eikon:  ID:nGNXc2bTc4 
Further company coverage:  ANGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))